Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
India
· Delayed Price · Currency is INR 3,354.10
+58.70 (1.78%)
Aug 14, 2025, 3:29 PM IST
Dr. Lal PathLabs Revenue
Dr. Lal PathLabs had revenue of 6.70B INR in the quarter ending June 30, 2025, with 11.28% growth. This brings the company's revenue in the last twelve months to 25.29B, up 10.57% year-over-year. In the fiscal year ending March 31, 2025, Dr. Lal PathLabs had annual revenue of 24.61B with 10.54% growth.
Revenue (ttm)
25.29B
Revenue Growth
+10.57%
P/S Ratio
10.88
Revenue / Employee
5.08M
Employees
4,980
Market Cap
275.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 24.61B | 2.35B | 10.54% |
| Mar 31, 2024 | 22.27B | 2.10B | 10.40% |
| Mar 31, 2023 | 20.17B | -705.26M | -3.38% |
| Mar 31, 2022 | 20.87B | 5.06B | 32.01% |
| Mar 31, 2021 | 15.81B | 2.51B | 18.86% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Divi's Laboratories | 96.52B |
| Cipla | 274.80B |
| Apollo Hospitals Enterprise | 217.94B |
| Mankind Pharma | 129.10B |
| Zydus Lifesciences | 232.42B |
| Fortis Healthcare | 80.94B |
| Aurobindo Pharma | 320.25B |
Dr. Lal PathLabs News
- 7 weeks ago - Dr Lal PathLabs, Metropolis Healthcare shares decline as Amazon Diagnostics enters market - Business Upturn
- 7 weeks ago - Dr Lal PathLabs shares decline 2% as Amazon enters diagnostics segment with doorstep lab tests - Business Upturn
- 3 months ago - Dr. Lal PathLabs Q4 FY25: Revenue up 10.48% to 602.6 crore, Net profit surges 81% YoY - Business Upturn
- 10 months ago - Dr Lal Path Labs stock jumps 3.46% after strong Q2 earnings and positive brokerage calls - Business Upturn
- 10 months ago - Dr Lal Path Labs share price: Buy, Sell, or Hold? Check what brokerages are saying - Business Upturn
- 10 months ago - UBS maintains buy call on Dr LalPath Labs, expects 7.7% upside in share price - Business Upturn
- 10 months ago - Dr Lal PathLabs Q2 FY25: Revenue up 9.8% YoY to ₹660.2 crore, net profit rises 18.1% YoY to ₹130.8 crore - Business Upturn
- 10 months ago - Nomura maintains ‘Buy’ on Dr Lal PathLabs, target price set at ₹3,720 - Business Upturn